Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cybin ( (TSE:CYBN) ) has shared an announcement.
Cybin announced that its Chief Business Officer, George Tziras, will present at the Jefferies Global Healthcare Conference in London, highlighting the company’s commitment to advancing mental healthcare. This participation underscores Cybin’s strategic efforts to strengthen its industry position and engage with stakeholders, potentially impacting its operations and market presence.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems. It is developing novel treatments like CYB003 and CYB004 for mental health conditions such as major depressive disorder and generalized anxiety disorder. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
Learn more about CYBN stock on TipRanks’ Stock Analysis page.